Abstract: Self-sustained, safe, stable and scalable microbial consortia (S5MicroCon) are described. The microbial consortia are regulated by photoautotroph-heterotroph interactions and RNA aptamer-based gene circuits. A rapid, high-throughput method for engineering RNA aptamer-based gene circuits (e.g. riboswitches) is also described.

Abstract: The present invention provides oligonucleotide constructs, sets of such oligonucleotide constructs, and methods of using such oligonucleotide constructs to provide validated sequences or sets of validated sequences corresponding to desired ROIs. Such validated ROIs and constructs containing these have a wide variety of uses, including in synthetic biology, quantitative nucleic acid analysis, polymorphism and/or mutation screening, and the like.

Abstract: The invention relates to genomically recoded organisms, platforms for preparing sequence defined biopolymers in vitro comprising a cellular extract from a genomically recorded organism, and methods for preparing sequence defined biopolymers in vitro are described. In particular, the invention relates to genomically recoded organisms comprising a strain deficient in release factor 1 (RF-1) or a genetic homolog thereof and at least one of at least one additional genetic knock-out mutation, at least one additional upregulated gene product, or both at least one additional knock-out mutation and at least one additional upregulated gene product.

Abstract: Disclosed are yeast cells expressing TAR DNA-binding protein 43 (TDP-43) and methods of screening yeast cells to identify compounds that prevent or suppress TDP-43-induced toxicity, compounds that inhibit the formation or maintenance of cytoplasmic inclusions of TDP-43, genetic suppressors or enhancers of TDP-43-induced toxicity, and genetic suppressors or enhancers of the formation or maintenance of cytoplasmic inclusions of TDP-43. Compounds identified by such screens can be used to treat or prevent TDP-43 proteinopathies such as frontotemporal lobar degeneration or amyotrophic lateral sclerosis.

Abstract: Aspects of the invention relate to reconfigurable chassis that allow for rapid construction and optimization of biocircuits.

Abstract: Method and apparatus for controlling acoustic treatment of a sample to mediate a tagmentation process used on double stranded DNA.

Abstract: A recombinant or isolated integrin heterodimer comprising a novel subunit ?10 in association with a subunit ? is described. The ?10 integrin may be purified from bovine chondrocytes on a collagen-type-II affinity column. The integrin or the subunit of ?10 can be used as a marker or target of all types of cells, e.g. of chondrocytes, osteoblasts, and fibroblasts. The integrin or the subunit ?10 thereof can be used as a marker or target in different physiological or therapeutic methods. They can also be used as active ingredients in pharmaceutical compositions and vaccines.

Abstract: Provided herein are methods and compositions for rapid assembly of genetic modules, as well as seamless transition from in vitro to in vivo testing of genetic constructs.

Abstract: The present disclosure provides methods and compositions for directed to synthetic block copolymer proteins, expression constructs for their secretion, recombinant microorganisms for their production, and synthetic fibers (including advantageously, microfibers) comprising these proteins that recapitulate many properties of natural silk. The recombinant microorganisms can be used for the commercial production of silk-like fibers.

Abstract: A platform for preparing a sequence defined biopolymer in vitro is disclosed. The platform includes a ribosome-depleted cellular extract ribosomal RNAs prepared by in vitro transcription and purified ribosomal proteins depleted of ribosomal RNAs. A method of synthesizing and assembling ribosomes in vitro for use in the platform is provided, as well as a method for preparing a sequence defined biopolymer in vitro using assembling ribosomes and the platform.

Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated rAAV constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.

Abstract: In the present invention, a method for the qualitative genetic characterization and/or gene expression characterization of predetermined cells in a fluid sample containing such cells is provided.

Abstract: The present invention relates to a gene which codes an enzyme having conversion activity between acetoin and 2,3-butanediol and has a nucleotide sequence of SEQ ID NO: 12. Further, the present invention relates to a protein coded by the gene. Further, the present invention relates to a recombinant microorganism having suppressed activity of the protein.

Abstract: The present invention provides oligonucleotide constructs, sets of such oligonucleotide constructs, and methods of using such oligonucleotide constructs to provide validated sequences or sets of validated sequences corresponding to desired ROIs. Such validated ROIs and constructs containing these have a wide variety of uses, including in synthetic biology, quantitative nucleic acid analysis, polymorphism and/or mutation screening, and the like.

Abstract: A DNA molecule comprising the sequence set forth in SEQ ID NO: 1, a recombinant Pichia plasmid into which the DNA molecule is inserted, and a recombinant Pichia strain obtained by the transformation of the recombinant Pichia plasmid into a competent Pichia cell and efficiently expressing the PprI protein of Deinococcus radiodurans.

Abstract: Disclosed herein, in certain instances, are methods for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods for determining the treatment modality of a cancer in a subject. The methods comprise expression-based analysis of targets. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject.

Abstract: The present invention relates to a method for producing a protein of interest containing one or more disulfide bonds in its native state. The method comprises that a prokaryotic host cell is genetically engineered to express the protein of interest and a sulfhydryl oxidase in the cytoplasm of the host cell. The protein of interest is formed in a soluble form and contains disulfide bonds due to the presence of the sulfhydryl oxidase in the cytoplasm of said host cell. The present invention relates also to a prokaryotic host cell and a vector system for producing a protein of interest containing natively folded disulfide bonds.

Abstract: The present invention relates to the decontamination of anthrax spores, prophylaxis and treatment of anthrax infections and, more particularly, to compounds that act as specific inhibitors of B. anthracis germination/outgrowth-associated proteins, methods and means for making such inhibitors and their use as pharmaceuticals and/or vaccines. The invention also relates to the prophylaxis and treatment of anthrax infections and, more particularly, to vaccines and compositions that comprise B. anthracis antigens, epitopes, proteins, or nucleic acid molecules, including anthrax protective antigen, anthrax lethal factor, anthrax edema factor and anthrax proteins associated with spore germination and outgrowth, as well as methods and means for making such compositions and their use pharmaceuticals and/or vaccines.

Abstract: The invention provides an organism for expressing foreign DNA, the organism engineered to accept standard DNA carriers. The genome of the organism codes for intracytoplasmic membranes and features an interruption in at least one of the genes coding for restriction enzymes. Further provided is a system for producing biological materials comprising: selecting a vehicle to carry DNA which codes for the biological materials; determining sites on the vehicle's DNA sequence susceptible to restriction enzyme cleavage; choosing an organism to accept the vehicle based on that organism not acting upon at least one of said vehicle's sites; engineering said vehicle to contain said DNA; thereby creating a synthetic vector; and causing the synthetic vector to enter the organism so as cause expression of said DNA.

Abstract: The present disclosure provides methods and compositions for directed to synthetic block copolymer proteins, expression constructs for their secretion, recombinant microorganisms for their production, and synthetic fibers (including advantageously, microfibers) comprising these proteins that recapitulate many properties of natural silk. The recombinant microorganisms can be used for the commercial production of silk-like fibers.